Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?

Bibliography

• Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2011; [Epub ahead of print]
   Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
   PubMed Web of Science ®Google Scholar
• Perry JR, Belanger K, Mason WP, Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010;28:2051-7
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol 2009;27:1268-74
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
   PubMed Web of Science ®Google Scholar
• Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91
   PubMed Web of Science ®Google Scholar
• Klagsbrun M, Sasse J, Sullivan R, Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci 1986;83:2448-52
   PubMed Web of Science ®Google Scholar
• . Lieu C, Heymach J, Overman M, Beyond VEGF. Inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011;17:6130-9
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114:853-65
   PubMed Web of Science ®Google Scholar
• Bates DO, Cui T-G, Doughty JM, VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002;62:4123-31
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307
   PubMed Web of Science ®Google Scholar
• Wu FTH, Stefanini MO, Gabhann FM, A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2009;14:528-52
   PubMed Web of Science ®Google Scholar
• Ikeda T, Sun L, Tsuruoka N, Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing. Biochem J 2011;436:399-407
   PubMed Web of Science ®Google Scholar
• Knizetova P, Ehrmann J, Hlobilkova A, Autocrine regulation of glioblastoma cell-cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 2008;7:2553-61
   PubMed Web of Science ®Google Scholar
• Steiner H-H, Karcher S, Mueller MM, Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 2004;66:129-38
   PubMed Web of Science ®Google Scholar
• Fischer C, Mazzone M, Jonckx B, FLT1 and its ligands VEGFB and PlGF: drug targets for antiangiogenic therapy? Nat Rev Cancer 2008;8:942-56
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M, Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75
   PubMed Web of Science ®Google Scholar
• Bagley RG, Ren Y, Weber W, Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res 2011;17:976-88
   PubMed Web of Science ®Google Scholar
• Bais C, Wu X, Yao J, PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141:166-77
   PubMed Web of Science ®Google Scholar
• Van de Veire S, Stalmans I, Heindryckx F, Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010;141:178-90
   PubMed Web of Science ®Google Scholar
• Yao J, Wu X, Zhuang G, Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci 2011;108:11590-5
   PubMed Web of Science ®Google Scholar
• Robinson SD, Hodivala-Dilke KM. The role of beta3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 2011;23:630-7
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74
   PubMed Web of Science ®Google Scholar
• Seegar TCM, Eller B, Tzvetkova-Robev D, Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 2010;37:643-55
   PubMed Web of Science ®Google Scholar
• Kunkel P, Ulbricht U, Bohlen P, Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001;61:6624-8
   PubMed Web of Science ®Google Scholar
• El Hallani S, Boisselier B, Peglion F, A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010;133:973-82
   Google Scholar
• Wang R, Chadalavada K, Wilshire J, Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Pallini R, Biffoni M, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8
   PubMed Web of Science ®Google Scholar
• Soda Y, Marumoto T, Friedmann-Morvinski D, Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci 2011;108:4274-80
   PubMed Web of Science ®Google Scholar
• Ma J, Chen C-S, Blute T, Antiangiogenesis enhances intratumoral drug retention. Cancer Res 2011;71:2675-85
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50
   PubMed Web of Science ®Google Scholar
• Heddleston JM, Li Z, McLendon RE, The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009;8:3274-84
   PubMed Web of Science ®Google Scholar
• Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011;76:87-93
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31
   PubMed Web of Science ®Google Scholar
• de Groot JF, Fuller G, Kumar AJ, Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncol 2010;12:233-42
   PubMed Web of Science ®Google Scholar
• Wick A, Dorner N, Schafer N, Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011;69:586-92
   PubMed Web of Science ®Google Scholar
• Narayana A, Kunnakkat SD, Medabalmi P, Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 2012;82:77-82
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Connor SJ, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-9
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-9
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5
   PubMed Web of Science ®Google Scholar
• Norden A, Bartolomeo J, Tanaka S, Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012;106:121-5
   PubMed Web of Science ®Google Scholar
• Nghiemphu PL, Green RM, Pope WB, Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008;10:355-60
   PubMed Web of Science ®Google Scholar
• Wick W, Weller M, van den Bent M, Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 2010;28:e188-e9
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72
   PubMed Web of Science ®Google Scholar
• Verhoeff J, van Tellingen O, Claes A, Concerns about antiangiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444
   PubMed Web of Science ®Google Scholar
• de Groot JF, Fuller G, Kumar AJ, Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncol 2010;12:233-42
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, Bevacizumab for recurrent malignant gliomas. Neurology 2008;70:779-87
   PubMed Web of Science ®Google Scholar
• Pope WB, Xia Q, Paton VE, Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76:432-7
   PubMed Web of Science ®Google Scholar
• Chinot O, de La Motte Rouge T, Moore N, AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011;28:334-40
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu PL, Phase II Study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29:142-8
   PubMed Web of Science ®Google Scholar
• Gururangan S, Chi SN, Young Poussaint T, Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010;28:3069-75
   PubMed Web of Science ®Google Scholar
• Nghiemphu PL, Liu W, Lee Y, Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-22
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Byrne AT, Ross L, Holash J, Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-8
   PubMed Web of Science ®Google Scholar
• Kim ES, Serur A, Huang J, Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proce Natl Acad Sci 2002;99:11399-404
   PubMed Web of Science ®Google Scholar
• Verheul HMW, Hammers H, van Erp K, Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007;13:4201-8
   PubMed Web of Science ®Google Scholar
• Gomez-Manzano C, Holash J, Fueyo J, VEGF Trap induces antiglioma effect at different stages of disease. Neuro-oncol 2008;10:940-5
   PubMed Web of Science ®Google Scholar
• de Groot JF, Lamborn KR, Chang SM, Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011;29:2689-95
   PubMed Web of Science ®Google Scholar
• Brave SR, Ratcliffe K, Wilson Z, Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther 2011;10:861-73
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400
   PubMed Web of Science ®Google Scholar
• Kamoun WS, Ley CD, Farrar CT, Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27:2542-52
   PubMed Web of Science ®Google Scholar
• Drevs J, Siegert P, Medinger M, Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-54
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28:2817-23
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a phase III randomized study [abstract OT-25]. Neuro Oncol 2010;12(Suppl 4):iv69-78
   Google Scholar
• Hu B, Guo P, Bar-Joseph I, Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF//SF autocrine pathway. Oncogene 2007;26:5577-86
   PubMed Web of Science ®Google Scholar
• Wick W, Grimmel C, Wild-Bode C, Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 2001;21:3360-8
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308
   PubMed Web of Science ®Google Scholar
• Wen PY, Prados M, Schiff D, Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients with progressive glioblastoma. J Clin Oncol 2010;28(Suppl):abstract 2006
   Google Scholar
• Kurzrock R, Sherman SI, Ball DW, Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6
   PubMed Web of Science ®Google Scholar
• Faul MM, Gillig JR, Jirousek MR, Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 2003;13:1857-9
   PubMed Web of Science ®Google Scholar
• Suzuma K, Takahara N, Suzuma I, Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci 2002;99:721-6
   PubMed Web of Science ®Google Scholar
• Keyes K, Mann L, Sherman M, LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133-40
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9
   PubMed Web of Science ®Google Scholar
• Tabatabai G, Frank B, Wick A, Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007;61:153-61
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kotliarova S, Butman JA, A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-oncol 2010;12:181-9
   PubMed Web of Science ®Google Scholar
• Butowski N, Chang SM, Lamborn KR, Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro-oncol 2011;13:1331-8
   PubMed Web of Science ®Google Scholar
• Goodman SL, Holzemann G, Sulyok AG, Nanomolar small molecule inhibitors for alphav(beta)5, and alphav(beta)3 integrins. J Med Chem 2002;45:1045-51
   PubMed Web of Science ®Google Scholar
• Nisato R, Tille J-C, Jonczyk A, alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003;6:105-19
   PubMedGoogle Scholar
• MacDonald TJ, Taga T, Shimada H, Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001;48:151-7
   PubMed Web of Science ®Google Scholar
• Maurer GD, Tritschler I, Adams B, Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-oncol 2009;11:747-56
   PubMed Web of Science ®Google Scholar
• Mikkelsen T, Brodie C, Finniss S, Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009;124:2719-27
   PubMed Web of Science ®Google Scholar
• MacDonald TJ, Stewart CF, Kocak M, Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26:919-24
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Rosenfeld SS, Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007;25:1651-7
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T, Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. J Clin Oncol 2008;26:5610-17
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Batchelor T, NABTT 0306: a randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 2009;27(Suppl):abstract 2001
   Google Scholar
• Stupp R, Hegi ME, Neyns B, Phase I/IIa Study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:2712-18
   PubMed Web of Science ®Google Scholar
• Stupp R, Bent MJVD, Erridge SC, Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). J Clin Oncol 2010;28(Suppl):abstract TPS152
   Google Scholar
• Kerbel RS, Kamen BA. The antiangiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36
   PubMed Web of Science ®Google Scholar
• Neyns B, Sadones J, Chaskis C, Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 2011;103:491-501
   PubMed Web of Science ®Google Scholar
• Wen PY, Cloughesy T, Kuhn J, Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol 2009;27(Suppl):abstract 2006
   Google Scholar
• Le Tourneau C, Faivre S, Serova M, mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008;99:1197-203
   PubMed Web of Science ®Google Scholar
• Lickliter J, Fida R, Wheeler H, Carboplatin combined with the vascular-disrupting agent CYT997 for recurrent glioblastoma multiforme. J Clin Oncol 2010;28(Suppl):abstract e13591
   Google Scholar
• Reardon D, Desjardins A, Peters K, Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 2011; [Epub ahead of print]
   Google Scholar
• Sathornsumetee S, Desjardins A, Vredenburgh JJ, Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-oncol 2010;12:1300-10
   PubMed Web of Science ®Google Scholar
• McGee MC, Hamner JB, Williams RF, Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010;76:1537-45
   PubMed Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K, Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-63
   PubMed Web of Science ®Google Scholar